We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coca-Cola (KO) Q3 Earnings & Sales Beat Estimates, Stock Up
Read MoreHide Full Article
The Coca-Cola Company (KO - Free Report) has delivered third-quarter 2020 results, wherein earnings and sales beat estimates. Comparable earnings of 55 cents per share beat the Zacks Consensus Estimate of 45 cents but declined 2% from the year-ago period. Currency translations negatively impacted earnings by 7%. Comparable currency-neutral earnings per share rose 5%.
Revenues of $8,652 million surpassed the Zacks Consensus Estimate of $8,353 million but declined 9% year over year. Organic revenues were down 6% from the prior-year quarter. The company’s top line declined from the prior year, owing to headwinds in the away-from-home channels, which accounts for nearly half of its total revenues. This was partly offset by sustained improvement in the at-home channels. Nonetheless, the company’s third-quarter revenues reflected improved trends from the second quarter.
During the quarter, concentrate sales declined 4% and price/mix was down 3%. Moreover, currency headwinds hurt the company’s top line by 3%.
During the quarter, it lost global value share in total non-alcoholic ready-to-drink (NARTD) beverages. The decline was attributed to a negative channel mix due to softness in the away-from-home channels, where it has a majority share position. This more than offset the overall underlying share gains.
Notably, the company’s shares gained 1.9% in the pre-market trading session, owing to the better-than-expected performance. Overall, the Zacks Rank #3 (Hold) stock has gained 3.5% in the past three months compared with the industry’s growth of 1.9%.
Volume and Pricing
Price/mix was down 3%, driven by adverse channel and package mix in key markets due to the coronavirus outbreak. Also, negative mix in the Global Ventures and Bottling Investments segment impacted price/mix. Concentrate sales were in line with unit case volume.
Coca-Cola’s total unit case volume was down 4% in the third quarter on declines in all operating segments, owing to pressures in the away-from-home channels due to the coronavirus outbreak. This was partly offset by continued strength in at-home channels.
CocaCola Company The Price, Consensus and EPS Surprise
Category Cluster Performance: Sparkling soft drinks’ unit case volume edged down 1% (compared with a 12% decline in the prior quarter), driven by declines in the fountain business in North America and Mexico, mainly owing to a decline in away-from-home channels. The Coca-Cola trademark was up 1%, with Coca-Cola Zero Sugar improving 7%. Volume for juice, dairy and plant-based beverages declined 6% (compared with a 20% fall in the last reported quarter). This category was primarily impacted by softness in the Asia Pacific and Latin America operating segments, which more than offset the strength in Simply and fairlife in North America.
Water, enhanced water and sports drinks fell 11% (compared with a 24% decline in the second quarter), mainly owing to broad-based declines across operating segments, particularly for the lower-margin water brands. Tea and coffee volume dropped 15% (compared with a 31% decline in the second quarter), owing to pandemic-led disruptions at the Costa retail stores as well as headwinds in the do??adan tea business in Turkey.
Segmental Details
Revenues declined 2% for North America, 23% for Latin America, 9% for the Asia Pacific, 7% for Europe, Middle East & Africa (“EMEA”), 12% for Bottling Investments, and 19% for Global Ventures segments.
Organic revenues fell 4% in Latin America, 3% in North America, 8% in the Asia Pacific, 6% in EMEA, 20% in Global Ventures segments and 6% in Bottling Investments.
Margins
Comparable currency-neutral operating income improved 7% year over year, driven by effective cost-management initiatives across all operations, partly offset by top-line pressures due to the pandemic. Comparable operating margin expanded 230 basis points (bps) to 30.4%. In dollar terms, comparable operating income declined 1.4% to $2,629 million.
Guidance
Though the company did not provide guidance for the fourth quarter and 2020 due to the uncertainties related to the coronavirus pandemic, it outlined the expected currency impacts on its results for both periods.
For 2020, it estimates currency headwinds of 3% on comparable net revenues and 6% on comparable operating income, based on current rates and hedge positions. The company expects underlying effective tax rate of 19.5% for 2020.
For the fourth quarter, it expects currency impacts of 3% on comparable net revenues and 9% on comparable operating income.
Additionally, the company estimates minimal currency impacts on comparable net revenues and comparable operating income in 2021.
The Boston Beer Company, Inc. (SAM - Free Report) delivered an earnings surprise of 26.1%, on average, in the trailing four quarters. The company presently flaunts a Zacks Rank #1.
Brown-Forman Corporation (BF.B - Free Report) currently carries a Zacks Rank #2 (Buy). It delivered an earnings surprise of 8.2%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Coca-Cola (KO) Q3 Earnings & Sales Beat Estimates, Stock Up
The Coca-Cola Company (KO - Free Report) has delivered third-quarter 2020 results, wherein earnings and sales beat estimates. Comparable earnings of 55 cents per share beat the Zacks Consensus Estimate of 45 cents but declined 2% from the year-ago period. Currency translations negatively impacted earnings by 7%. Comparable currency-neutral earnings per share rose 5%.
Revenues of $8,652 million surpassed the Zacks Consensus Estimate of $8,353 million but declined 9% year over year. Organic revenues were down 6% from the prior-year quarter. The company’s top line declined from the prior year, owing to headwinds in the away-from-home channels, which accounts for nearly half of its total revenues. This was partly offset by sustained improvement in the at-home channels. Nonetheless, the company’s third-quarter revenues reflected improved trends from the second quarter.
During the quarter, concentrate sales declined 4% and price/mix was down 3%. Moreover, currency headwinds hurt the company’s top line by 3%.
During the quarter, it lost global value share in total non-alcoholic ready-to-drink (NARTD) beverages. The decline was attributed to a negative channel mix due to softness in the away-from-home channels, where it has a majority share position. This more than offset the overall underlying share gains.
Notably, the company’s shares gained 1.9% in the pre-market trading session, owing to the better-than-expected performance. Overall, the Zacks Rank #3 (Hold) stock has gained 3.5% in the past three months compared with the industry’s growth of 1.9%.
Volume and Pricing
Price/mix was down 3%, driven by adverse channel and package mix in key markets due to the coronavirus outbreak. Also, negative mix in the Global Ventures and Bottling Investments segment impacted price/mix. Concentrate sales were in line with unit case volume.
Coca-Cola’s total unit case volume was down 4% in the third quarter on declines in all operating segments, owing to pressures in the away-from-home channels due to the coronavirus outbreak. This was partly offset by continued strength in at-home channels.
CocaCola Company The Price, Consensus and EPS Surprise
CocaCola Company The price-consensus-eps-surprise-chart | CocaCola Company The Quote
Category Cluster Performance: Sparkling soft drinks’ unit case volume edged down 1% (compared with a 12% decline in the prior quarter), driven by declines in the fountain business in North America and Mexico, mainly owing to a decline in away-from-home channels. The Coca-Cola trademark was up 1%, with Coca-Cola Zero Sugar improving 7%. Volume for juice, dairy and plant-based beverages declined 6% (compared with a 20% fall in the last reported quarter). This category was primarily impacted by softness in the Asia Pacific and Latin America operating segments, which more than offset the strength in Simply and fairlife in North America.
Water, enhanced water and sports drinks fell 11% (compared with a 24% decline in the second quarter), mainly owing to broad-based declines across operating segments, particularly for the lower-margin water brands. Tea and coffee volume dropped 15% (compared with a 31% decline in the second quarter), owing to pandemic-led disruptions at the Costa retail stores as well as headwinds in the do??adan tea business in Turkey.
Segmental Details
Revenues declined 2% for North America, 23% for Latin America, 9% for the Asia Pacific, 7% for Europe, Middle East & Africa (“EMEA”), 12% for Bottling Investments, and 19% for Global Ventures segments.
Organic revenues fell 4% in Latin America, 3% in North America, 8% in the Asia Pacific, 6% in EMEA, 20% in Global Ventures segments and 6% in Bottling Investments.
Margins
Comparable currency-neutral operating income improved 7% year over year, driven by effective cost-management initiatives across all operations, partly offset by top-line pressures due to the pandemic. Comparable operating margin expanded 230 basis points (bps) to 30.4%. In dollar terms, comparable operating income declined 1.4% to $2,629 million.
Guidance
Though the company did not provide guidance for the fourth quarter and 2020 due to the uncertainties related to the coronavirus pandemic, it outlined the expected currency impacts on its results for both periods.
For 2020, it estimates currency headwinds of 3% on comparable net revenues and 6% on comparable operating income, based on current rates and hedge positions. The company expects underlying effective tax rate of 19.5% for 2020.
For the fourth quarter, it expects currency impacts of 3% on comparable net revenues and 9% on comparable operating income.
Additionally, the company estimates minimal currency impacts on comparable net revenues and comparable operating income in 2021.
Don’t Miss These Better-Ranked Beverage Stocks
National Beverage Corp. (FIZZ - Free Report) delivered an earnings surprise of 26.6%, on average, in the trailing four quarters. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Boston Beer Company, Inc. (SAM - Free Report) delivered an earnings surprise of 26.1%, on average, in the trailing four quarters. The company presently flaunts a Zacks Rank #1.
Brown-Forman Corporation (BF.B - Free Report) currently carries a Zacks Rank #2 (Buy). It delivered an earnings surprise of 8.2%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>